Encellin raises about $10M for type 1 diabetes cell replacement therapy
Encellin raised $9.9 million to join the burgeoning type 1 diabetes space with its own cell replacement therapy and first-in-human data expected next year.
The small team at the San Francisco-based company employs fewer than five people, who developed what they call encapsulated cell replacement therapy (EnCRT) — a porous device that holds cadaveric primary islets that can be subcutaneously inserted in a patient and secrete islets when needed to manage type 1 diabetes. In type 1 patients, the islet cells located in the pancreas are destroyed or damaged by the immune system and don’t make insulin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
